Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia

Abstract Background The combination of venetoclax (VEN) with hypomethylating agents (HMAs) has emerged as a new standard treatment for older or unfit patients with acute myeloid leukemia (AML). However, the predictive factors for VEN/HMA efficacy remain unclear. In our study, we performed the first...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:European Journal of Medical Research
المؤلفون الرئيسيون: Wenxiu Shu, Qianqian Yang, Donghua He, Yi Li, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Bingrong Chen, Yuan Gong, Dian Jin
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2025-05-01
الموضوعات:
Acute myeloid leukemia
KIT
Venetoclax
Hypomethylating agents
Chemotherapy
Prognosis
الوصول للمادة أونلاين:https://doi.org/10.1186/s40001-025-02637-w

الانترنت

https://doi.org/10.1186/s40001-025-02637-w

مواد مشابهة